Michael Henderson, M.D.
Dr. Henderson joined BridgeBio to bring genetically targeted treatments to patients with the highest unmet need. As BridgeBio’s senior vice president of asset acquisition, strategy and operations, Dr. Henderson is responsible for identifying and bringing in new technologies, furthering the overarching strategy of BridgeBio, and playing an operator role in the parent and subsidiary companies. He has overseen the creation of 15 companies to date and is currently serving as interim chief business officer for QED Therapeutics. Dr. Henderson is a voting board member for five of BridgeBio’s subsidiary companies and cofounded one of BridgeBio’s portfolio companies, PellePharm, while in medical school. Prior to BridgeBio, he was a consultant in McKinsey & Company’s Silicon Valley office, where he served biotech clients across the U.S. and European Union. He received his B.A. from Harvard University and holds an M.D. from Stanford University.